VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
– Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa 
– VNRX-5133 may provide a therapeutic option for these emerging pathogens, which are classified as urgent public health threats by the Centers for Disease Control and Prevention

See more here